NCT04990310View on ClinicalTrials.gov

Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 18, 2021

Primary Completion Date

September 20, 2021

Study Completion Date

September 20, 2021

Conditions
Healthy
Interventions
DRUG

[14C]-CORT113176

\[14C\]-CORT113176 450 mg lipid formulation capsule for oral administration containing not more than 3.37 megaBequerel 14C.

Trial Locations (1)

NG11 6JS

Site 01, Ruddington

Sponsors
All Listed Sponsors
lead

Corcept Therapeutics

INDUSTRY